Recommendations for diagnosis and management of metformin-induced vitamin B12 (Cbl) deficiency

Diabetes Res Clin Pract. 2012 Sep;97(3):359-67. doi: 10.1016/j.diabres.2012.06.001. Epub 2012 Jul 7.

Abstract

Metformin treatment is a known pharmacological cause of vitamin B12 (Cbl) deficiency with controversial responsible mechanisms. A possible diagnosis of this deficiency is based mainly on the combination of patient's medical history (usually long-term metformin use), clinical examination (possible neuropsychiatric symptoms and signs), laboratory studies which confirm a Cbl deficiency (haematological abnormalities, low serum Cbl levels, elevated serum total homocysteine and methylmalonic acid levels), and exclusion other causes of Cbl deficiency (as pernicious anaemia, food-cobalamin malabsorption syndrome, other drugs, etc.). In our review, recommendations for diagnosis and management of metformin-induced Cbl deficiency (MICD) in diabetic patients based on medical bibliography are presented and discussed.

Publication types

  • Review

MeSH terms

  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use
  • Metformin / adverse effects*
  • Metformin / therapeutic use
  • Models, Biological
  • Practice Guidelines as Topic*
  • Prevalence
  • Vitamin B 12 Deficiency / chemically induced*
  • Vitamin B 12 Deficiency / diagnosis*
  • Vitamin B 12 Deficiency / epidemiology
  • Vitamin B 12 Deficiency / therapy*

Substances

  • Hypoglycemic Agents
  • Metformin